Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody.

Lung Cancer

Department of Thoracic Oncology, Antwerp University Hospital, Edegem, Belgium; Center for Oncological Research, University of Antwerp, Antwerp, Belgium.

Published: July 2017

A 58-year-old man was being treated for squamous non-small-cell lung cancer with nivolumab. At the 17th of biweekly administrations he presented with global dysphasia, dysarthria and myoclonus in the right upper extremity. MRI showed multiple T2/FLAIR hyperintense lesions in the left hemisphere; lumbar puncture showed lymphocytic pleiocytosis in the CSF without identifiable pathogens. Hu antibodies were present in serum and CSF. Nivolumab was discontinued and corticosteroids were administered. The neurological symptoms gradually improved; MRI showed complete remission of cerebral lesions. After rechallenge with nivolumab his symptoms and cerebral lesions recurred, proving the causal relationship with nivolumab. After tapering of corticosteroids, a second relapse occurred.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.05.002DOI Listing

Publication Analysis

Top Keywords

cerebral lesions
8
recurrent dysphasia
4
dysphasia nivolumab-induced
4
nivolumab-induced encephalopathy
4
encephalopathy presence
4
presence autoantibody
4
autoantibody 58-year-old
4
58-year-old man
4
man treated
4
treated squamous
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!